Characteristic | N (%) |
---|---|
Age (years) | |
  ≤ 40 | 23(26.4%) |
 41–50 | 27(31.1%) |
  > 50 | 37(42.5%) |
Histologic subtype | |
 No special type | 85(97.7%) |
 lobular | 2(2.3%) |
Tumor size (cm) | |
  ≤ 0.5 | 1(1.1%) |
  > 0.5, ≤ 1 | 20(23.0%) |
  > 1, ≤ 2 | 66(75.9%) |
Histologic Grade | |
 1 | 17(19.6%) |
 2 | 59(67.8%) |
 3 | 11(12.6%) |
Ki67 | |
  ≤ 30% | 16(18.4%) |
  > 30% | 71(81.6%) |
P53 | |
 Positive | 25(28.7%) |
 Negative | 62(71.3%) |
Basal-like marker | |
 Positive | 12(13.8%) |
 Negative | 75(86.2%) |
TILs | |
  ≤ 10% | 65(74.7%) |
 11–59% | 19(21.8%) |
  ≥ 60% | 3(3.5%) |
IHC surrogated subtype | |
 Luminal A | 61(32.2%) |
 Luminal B | 26(67.8%) |
Immune score | |
 Strong | 43(49.4%) |
 Weak | 44(50.6%) |
Chemotherapy | |
 Yes | 26(29.9%) |
 No | 61(70.1%) |
Endocrine therapy | |
 Yes | 87(100%) |
 No | 0(0%) |
Radiotherapy | |
 Yes | 25(28.7%) |
 No | 62(71.3%) |
Recurrent status | |
 Yes | 26(29.9%) |
 No | 61(70.1%) |
Distant metastasis | |
 Yes | 15(17.2%) |
 No | 72(82.8%) |
Living status | |
 Yes | 84(96.6%) |
 No | 3(3.4%) |